PTCT
PTC Therapeutics Inc
63.50$
-1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +209.3% | +1,892.4% | -70.9% | +8.9% | -26.7% | +60.1% | +124.9% | +135.0% | +36.2% | +16.0% | +24.0% | +41.4% | +29.7% | +34.2% | -14.0% | +114.5% | |
| – | +11.9% | +160.7% | -107.2% | – | +45.5% | +52.6% | -3.4% | -96.1% | +176.8% | -4.2% | +56.1% | +70.7% | +38.2% | +46.6% | -12.4% | +25.0% | |
| – | – | – | -65.7% | -169.4% | – | – | +124.9% | +129.5% | +32.8% | +17.0% | +22.7% | +39.9% | +29.2% | +33.4% | -14.1% | +121.4% | |
| – | +5.2% | +177.8% | -21.4% | +18.9% | +45.5% | +52.6% | -3.4% | -0.2% | +46.4% | +49.7% | +85.5% | +13.2% | +20.5% | +2.3% | -19.8% | -14.8% | |
| – | – | – | -9.5% | +72.5% | +77.7% | +83.1% | +18.3% | +24.9% | +26.6% | +31.9% | +21.0% | +16.4% | +5.2% | +16.3% | -13.8% | +15.4% | |
| – | – | – | -18.7% | +38.0% | +59.5% | +66.6% | +5.3% | +18.3% | +37.1% | +53.8% | +48.1% | +11.0% | +25.1% | +19.1% | -19.8% | -23.7% | |
| – | – | – | -187.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -50.5% | +402.8% | -80.6% | +100.6% | +249.6% | +46.1% | +3.8% | -0.5% | +351.1% | +52.7% | +5.6% | +42.2% | +29.3% | -8.8% | |
| – | – | – | -191.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +413.7% | -175.5% | – | +17.3% | +134.6% | -102.2% | – | +202.4% | -84.2% | -612.0% | – | – | +7,840.3% | |
| – | – | – | -184.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -172.1% | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.